// STATE LEGISLATION TRACKER

Arizona HB 2660: health boards; licensure decisions; investigation

⚖️ NEUTRAL for peptide users 👤 LOW user impact 📜 Status: Vetoed

State: Arizona
Bill: HB 2660
Session: 57th-2nd-regular
Filed: 2026-01-20
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

HB2660 was a broad Arizona health-board discipline bill, not a peptide-specific bill. It did not directly change compounded peptide access, off-label prescribing, telehealth rules, 503A/503B compounding, controlled substances, or PDMP duties, and it was vetoed.

Key Points

No direct change to peptide prescribing or access in Arizona
No new rules for 503A/503B peptide compounding appear from this bill
NPs, naturopaths, and physicians stay under current board discipline rules
Could have affected whether clinicians keep practicing during license appeals
Veto means no current legal change for peptide patients or clinics

What to Watch For

Note A similar bill could return and affect how quickly boards can restrict a clinician's license.

✓

Opportunity Future versions may help clinicians keep practicing during appeals when no crime is charged.

Concern Delaying board discipline could make it harder to stop unsafe prescribers quickly.

Where the Bill Stands

The bill passed the legislature but was vetoed by the Arizona Governor on June 19, 2026, so it did not become law.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-06 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws